{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=42",
    "query": {
      "intervention": "cohort 4",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:30:52.736Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01542021",
      "title": "Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "degarelix injection",
          "type": "DRUG"
        },
        {
          "name": "androgen deprivation therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 41,
      "start_date": "2012-02-24",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01542021"
    },
    {
      "nct_id": "NCT01724814",
      "title": "A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "HM12460A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 86,
      "start_date": "2012-12-20",
      "completion_date": "2014-07-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724814"
    },
    {
      "nct_id": "NCT06834126",
      "title": "Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Rectal Adenocarcinoma",
        "Stage II Rectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Consolidation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Functional Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Gastrointestinal Endoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Papaverine",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Total Mesorectal Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2025-04-07",
      "completion_date": "2028-09-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834126"
    },
    {
      "nct_id": "NCT02371226",
      "title": "Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mucopolysaccharidosis I"
      ],
      "interventions": [
        {
          "name": "AGT-181 (HIRMAb-IDUA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArmaGen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-07",
      "completion_date": "2017-02-01",
      "has_results": false,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 6,
      "location_summary": "Oakland, California • Orange, California • Decatur, Georgia + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02371226"
    },
    {
      "nct_id": "NCT01088048",
      "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Indolent Non-Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Chlorambucil",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2010-03-25",
      "completion_date": "2015-04-28",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 11,
      "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088048"
    },
    {
      "nct_id": "NCT04248855",
      "title": "Assessment of KAN-101 in Celiac Disease (ACeD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Celiac Disease"
      ],
      "interventions": [
        {
          "name": "KAN-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 41,
      "start_date": "2020-01-21",
      "completion_date": "2021-10-08",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 13,
      "location_summary": "Anaheim, California • Walnut Creek, California • Aventura, Florida + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04248855"
    },
    {
      "nct_id": "NCT03701555",
      "title": "A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Digestive System Disease"
      ],
      "interventions": [
        {
          "name": "PvP001 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 300 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP001 900 mg",
          "type": "DRUG"
        },
        {
          "name": "Maximum Feasible Dose (MFD) of PvP002",
          "type": "DRUG"
        },
        {
          "name": "Maximum Tolerated Dose (MTD) of PvP001",
          "type": "DRUG"
        },
        {
          "name": "MTD of PvP001 following 7 days of PPI treatment",
          "type": "DRUG"
        },
        {
          "name": "PvP002 placebo",
          "type": "OTHER"
        },
        {
          "name": "PvP001 600 mg",
          "type": "DRUG"
        },
        {
          "name": "PvP003 placebo",
          "type": "DRUG"
        },
        {
          "name": "PvP003",
          "type": "DRUG"
        },
        {
          "name": "PvP003 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 139,
      "start_date": "2018-06-19",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701555"
    },
    {
      "nct_id": "NCT04720378",
      "title": "Safety and Tolerability Study of IV ST266 in COVID-19 Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytokine Release Syndrome"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-05-30",
      "completion_date": "2022-05-03",
      "has_results": false,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04720378"
    },
    {
      "nct_id": "NCT05205252",
      "title": "A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Hematologic Malignancy",
        "Refractory Hematologic Malignancy"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Tafasitamab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab (Intravenously)",
          "type": "DRUG"
        },
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab (Subcutaneously)",
          "type": "DRUG"
        },
        {
          "name": "Hyaluronidase-Fihj",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone 20mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-12-22",
      "completion_date": "2023-07-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 3,
      "location_summary": "Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey",
      "locations": [
        {
          "city": "Santa Fe",
          "state": "California"
        },
        {
          "city": "Bolivar",
          "state": "Missouri"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05205252"
    },
    {
      "nct_id": "NCT05160558",
      "title": "A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinocerebellar Ataxia Type 3"
      ],
      "interventions": [
        {
          "name": "BIIB132",
          "type": "DRUG"
        },
        {
          "name": "BIIB132-Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2022-02-02",
      "completion_date": "2023-07-25",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-11-19T08:30:52.736Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05160558"
    }
  ]
}